Pablo E. Pérgola

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Pablo E. Pérgola, Philip Raskin, Robert D. Toto et al. · New England Journal of Medicine · 2011 · 876 citations · Full text

Medicine, Endocrinology, Nephrology +16

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 667 citations

Medicine, Immunology, Pharmacology +14

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Sodium Zirconium Cyclosilicate in Hyperkalemia

David Packham, Henrik Rasmussen, Philip T. Lavin et al. · New England Journal of Medicine · 2014 · 493 citations · Full text

Medicine, Nephrology, Pharmacology +9

Cutaneous Active Vasodilation in Humans Is Mediated by Cholinergic Nerve Cotransmission

Dean L. Kellogg, Pablo E. Pérgola, Kenneth L. Piest et al. · Circulation Research · 1995 · 366 citations

Medicine, Pharmacology, Physiology +15